High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy

Journal of Immunology

Volumn 162, Issue 2, 1999, Pages 989-994

  Zeh III, Herbert J ^a   Perry Lalley, Donna ^a   Dudley, Mark E ^a   Rosenberg, Steven A ^a   Yang, James C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; ENVELOPE PROTEIN; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HOST RESISTANCE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033556322     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rosenberg, S. A. 1996. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. 88:1635.
2. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
3. Kawakami, Y., and S. A. Rosenberg. 1997. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol. 14:173.
4. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peplide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
5. Jeffee, E. M., and D. M. Pardoll. 1996. Murine tumor antigens: is it worth the search? Curr. Opin. Immunol. 8:622.
6. Bloom, M. B., D. Perry-Lalley, P. F. Robbins, Y. Li, M. El-Gamil, S. A. Rosenberg, and J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453.
7. Jaffee, E. M., M. C. Thomas, A. Y. Huang, K. M. Hauda, H. I. Levitsky, and D. M. Pardoll. 1996. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother. Emphas. Tumor Immunol. 19:176.
8. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102.
9. 27-35. J. Exp. Med. 184:647.
10. Critchfield, J. M., J. C. Racke, B. Zuniga-Pflucker, C. S. Cannella, J. Raine, J. Goverman, and M. J. Lenardo. 1998. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263:1139.
11. Iezzi, G., K. Karjalainen, and A. Lanzaveccia. 1998. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8:89.
12. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, and J. A. Berzofsky. 1996. Role of antigen, CDS, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485.
13. + tumor infiltrating lymphocytes. J. Exp. Med. 173:647.
14. Dudley, M. E., M. Nishimura, A. K. Holt, and S. A. Rosenberg. 1998. Anti-tumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J. Immunother. In press.
15. Toes, R. E., R. J. Blom, R. Offringa, W. M. Kast, and C. J. Melief. 1996. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156:3911.
16. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad Sci. USA 93:7855.